Project,Study_abbr,Study_full,DLMUSE N Baseline,DLMUSE N Followup,% Female,Age (mean ± SD),Country/Region,Start_Year,Ongoing,Primary_Description,Disease_Tags,Aging,Alzheimer,Cardiometabolic,Psychiatric,Population,Repository,Point of Contact Official,Point of Contact Unofficial,Manuscript,Website,DUA,Grants,Study_Overview,Data_Dictionary,CUBIC,Resting State(to Raw BIDS),Resting State Counts,DTI (to Raw BIDS),DTI Counts,Resting state (Derivatives),DTI(Derivatives),age_range,N_subject,N_MR_session,T1w_avai,fmri_avai,dmri_avai,fmap_avai,asl_avail,DLMUSE,DLMUSE_version,DLMUSE_N_ses_completed,DLWMLS,DLWMLS_version,DLWMLS_N_ses_completed,fMRIPrep,fMRIPrep_version,fMRIPrep_N_ses_completed,fMRIPrep_command,XCP-D,XCP-D_version,XCP-D_N_ses_completed,XCP-D_command,Status,,,
ISTAGING,ACCORD,Action to Control Cardiovascular Risk in Diabetes,605,760,44.6,62.9 ± 5.8,USA,2001,FALSE,Type 2 diabetes and cardiovascular outcomes,diabetes,0,0,1,0,0,0,,,https://pmc.ncbi.nlm.nih.gov/articles/PMC5633725/;https://pubmed.ncbi.nlm.nih.gov/21958949/,https://biolincc.nhlbi.nih.gov/studies/accord/?q=accord,https://biolincc.nhlbi.nih.gov/faq/,???,The Action to Control Cardiovascular Risk in Diabetes (ACCORD)  clinical trial evaluated intensive glycemic control on a cohort of participants with type 2 diabetes. The Memory in Diabetes (MIND) sub-study further evaluated cognitive and structural brain outcomes in a subset of participants from the two randomized groups of ACCORD study.,/cbica/projects/ISTAGING/Pipelines/ClinicalDataConsolidation_201911/dictionaries/ACCORD/ACCORD Data Dictionary.pdf,/cbica/projects/accord,NA,,NA,,NA,NA,40-79,629,1414,Yes,No,Yes,No,No,/cbica/projects/accord/Pipelines/ACCORD_DLMUSE_2025/Results/DLMUSE_Volumes.csv,version ???,1411,/cbica/projects/accord/Pipelines/ACCORD_DLWMLS_2025/Results/ACCORD_DLWMLS_DLMUSE_Segmented_Volumes.csv,version ???,1308,,,,,,,,,Added to website. TODO: Fill in the ???. Add any missing pipelines,,,
ISTAGING,ADNI,Alzheimer’s Disease Neuroimaging Initiative,2444,8410,47.7,73.1 ± 7.3,USA/Canada,2004,TRUE,Alzheimer's biomarkers and progression,alzheimers,0,1,0,0,0,0,,,https://pmc.ncbi.nlm.nih.gov/articles/PMC2809036/,http://adni.loni.usc.edu/,https://adni.loni.usc.edu/wp-content/themes/adni_2023/documents/ADNI_Data_Use_Agreement.pdf,"ADNI (National Institutes of Health Grant U01 AG024904, U01 AG072177) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012) are funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. MESA is supported by contracts 75N92020D00001, HHSN268201500003I, N01-HC-95159, 75N92020D00005, N01-HC-95160, 75N92020D00002, N01-HC-95161, 75N92020D00003, N01-HC-95162, 75N92020D00006, N01-HC-95163, 75N92020D00004, N01-HC-95164, 75N92020D00007, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168 and N01-HC-95169 from the National Heart, Lung, and Blood Institute, and by grants UL1-TR-000040, UL1-TR-001079, and UL1-TR-001420 from the National Center for Advancing Translational Sciences (NCATS). Brain MRI is supported by grant R01 HL127659 from the National Heart, Lung, and Blood Institute with additional support from the National Institute on Aging and grant R01 AG080821.","The Alzheimer’s Disease Neuroimaging Initiative (ADNI) is a public–private partnership coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. Since its launch in 2003 under the leadership of Principal Investigator Michael W. Weiner, MD, 63 sites across the United States and Canada have contributed to the ongoing effort to identify, track, and understand Alzheimer’s disease (AD) and its early stages. The study collects longitudinal multimodal data, including structural and functional MRI, positron emission tomography (PET) with FDG, PiB, and AV-45 tracers, biological samples (blood, urine, and cerebrospinal fluid in a subset), and comprehensive clinical and neuropsychological assessments from over 1,000 participants with AD, mild cognitive impairment (MCI), or age-matched controls.",https://adni.loni.usc.edu/data-samples/data-dictionary-search/,/cbica/projects/ADNI,Coming Soon,,NA,,Coming Soon,NA,55-90,2517,10913,Yes,No,No,No,No,/cbica/projects/ADNI/Pipelines/ADNI_DLMUSE_2025/Results/DLMUSE_Volumes.csv,version ???,10858,/cbica/projects/ADNI/Pipelines/ADNI_DLWMLS_2025/Results/ADNI_DLWMLS_DLMUSE_Segmented_Volumes.csv,version ???,6075,,,,,,,,,Added to website. TODO: Fill in the ???. Add any missing pipelines,,,
ISTAGING,ADNI-DOD,Alzheimer’s Disease Neuroimaging Initiative - Department of Defense,273,264,0.7,69.8 ± 4.6,USA,2009,TRUE,ADNI extension with DoD veterans cohort,alzheimers,0,1,0,0,0,0,,,https://pmc.ncbi.nlm.nih.gov/articles/PMC5526098/,,https://ida.loni.usc.edu/collaboration/access/appLicense.jsp,"ADNI (National Institutes of Health Grant U01 AG024904, U01 AG072177) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012) are funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. MESA is supported by contracts 75N92020D00001, HHSN268201500003I, N01-HC-95159, 75N92020D00005, N01-HC-95160, 75N92020D00002, N01-HC-95161, 75N92020D00003, N01-HC-95162, 75N92020D00006, N01-HC-95163, 75N92020D00004, N01-HC-95164, 75N92020D00007, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168 and N01-HC-95169 from the National Heart, Lung, and Blood Institute, and by grants UL1-TR-000040, UL1-TR-001079, and UL1-TR-001420 from the National Center for Advancing Translational Sciences (NCATS). Brain MRI is supported by grant R01 HL127659 from the National Heart, Lung, and Blood Institute with additional support from the National Institute on Aging and grant R01 AG080821.","The Alzheimer’s Disease Neuroimaging Initiative – Department of Defense is a study funded by the Department of Defense to examine if Traumatic Brain Injury (TBI) and posttraumatic stress disorder (PTSD) contribute to or cause Alzheimer’s Disease. The study recruits Vietnam Veterans with a positive history of either TBI or PTSD. This is assessed through the evaluation of amyloid PET, CSF Aβ and tau data.",https://adni.loni.usc.edu/data-samples/data-dictionary-search/,/cbica/projects/ADNI,NA,,NA,,NA,NA,,,,,,,,,/cbica/projects/ADNI/Pipelines/ADNI-DOD_DLMUSE_2025/Results/DLMUSE_Volumes.csv,,,,,,,,,,,,,,,,,
ISTAGING,AIBL,"Australian Imaging, Biomarkers & Lifestyle Study of Ageing",973,1003,56.1,73.0 ± 6.7,Australia,2006,TRUE,Alzheimer's disease and aging,alzheimers,1,1,0,0,0,0,,,https://pubmed.ncbi.nlm.nih.gov/19470201/,https://aibl.org.au/,https://ida.loni.usc.edu/collaboration/access/appApply.jsp?project=AIBL,,"The Australian Imaging, Biomarker, and Lifestyle (AIBL) study began in Perth and Melbourne, Australia between 2006-2008, as a longitudinal prospective research study of Alzheimer’s Disease led by the Australian Commonwealth Scientific Industrial and Research Organization (CSIRO). AIBL study enrolled 1,112 participants above the age of 60, with Alzheimer’s Disease (20%), Mild Cognitive Impairment (10%), and healthy controls (70%). The first assessment included cognitive testing, blood collection, and health and lifestyle questionnaires. MRI and PET neuroimaging using the Pittsburgh Compound B (PiB) tracer were initially acquired in only 287 AIBL participants. Following longitudinal assessments, occurring at 18-month intervals, have added neuroimaging to all participants and CSF collection for analysis of biomarkers. The cognitive assessment in AIBL was designed to cover main domains of cognition affected by Alzheimer’s disease. This 90-minute assessment was conducted in-clinic by trained staff, most of whom were neuropsychologists. A part of the data has been made publicly available via [https://aibl.csiro.au/adni/index.html].",/cbica/projects/ISTAGING/Pipelines/ClinicalDataConsolidation_201911/dictionaries/AIBL/PAC_AIBL_Data_Dictionary_Reorganized_20200901.csv,/cbica/projects/AIBL,NA,,NA,,NA,NA,,,,,,,,,/cbica/projects/AIBL/Pipelines/AIBL_DLMUSE_2025/Results/DLMUSE_Volumes.csv,,,,,,,,,,,,,,,,,
ISTAGING,BIOCARD,Biomarkers of Cognitive Decline Among Normal Individuals,299,826,58.5,58.3 ± 10.5,USA,1995,TRUE,Alzheimer's risk and cognitive decline,alzheimers,1,1,0,0,0,0,,,https://biocard.pathology.jhu.edu/biocard-study-publication-list/,https://www.biocard-se.org/public/BIOCARD%20Data%20Descriptions.html,https://biocard.pathology.jhu.edu/wp-content/uploads/2024/09/Data-Use-Agreement.pdf,The BIOCARD study is in part supported by NIH grant U19-AG033655.,"The Biomarkers of Cognitive Decline Among Normal Individuals (BIOCARD) study was initiated by the Geriatric Branch of the National Institute of Mental Health in 1995. To identify biomarkers associated with the progression of cognitive impairment, BIOCARD recruited 354 cognitively healthy adults including those with a first-degree relative affected with AD. BIOCARD participants were initially admitted for a three-day long evaluation at the Clinical Center at the National Institutes of Health (NIH). At this time, a detailed physical examination, neuropsychological assessment, brain MRI, and blood and cerebrospinal fluid (CSF) samples were obtained. Subsequently, annual evaluations were conducted at the NIH until the study closed in 2005. The Johns Hopkins School of Medicine re-opened the BIOCARD study in 2009, continuing with annual clinical and cognitive follow-up for the original BIOCARD cohort. Amyloid PET imaging using the Pi-B tracer began in 2015, and Tau PET imaging began in 2017. In BIOCARD, Johns Hopkins University continued to administer all the cognitive tests from the original protocol from NIH. The annual neuropsychological assessment covers every major cognitive domain (memory, executive function, language, visuospatial ability, attention, speed of processing, and psychomotor speed). This assessment includes TMT and CVLT cognitive tests of executive function and memory.",/cbica/projects/ISTAGING/Pipelines/ClinicalDataConsolidation_201911/dictionaries/BIOCARDPAC_BIOCARD_Data_Dictionary_Reorganized_20200901.csv,/cbica/projects/BIOCARD,NA,,NA,,NA,NA,,,,,,,,,/cbica/projects/BIOCARD/Pipelines/BIOCARD_DLMUSE_2025/Results/DLMUSE_Volumes.csv,,,,,,,,,,,,,,,,,
ISTAGING,BLSA,Baltimore Longitudinal Study of Aging,1139,2926,52.6,65.4 ± 14.1,USA,1958,TRUE,Normal aging and lifespan study,aging,1,0,0,0,0,0,,,,https://www.blsa.nih.gov/,https://blsa.nih.gov/blsa-data-use,"The Baltimore Longitudinal Study of Aging neuroimaging study is funded by the Intramural Research Program, National Institute on Aging, National Institutes of Health and by HHSN271201600059C.","The Baltimore Longitudinal Study of Aging (BLSA) is an ongoing longitudinal study led by the National Institute of Aging (NIA). The BLSA began in Baltimore, Maryland, USA in 1958, with the aim of characterizing the process of aging in general, and healthy aging in particular. The BLSA acquires physiological measures, biomarkers, risk factors, blood samples, and evaluates cognitive function in individuals healthy at enrollment over the course of their lifetime. The neuroimaging sub-study of BLSA began in 1994, with annual or semi-annual MR and PET imaging studies, cognitive testing, and clinical evaluations of a subset of 158 BLSA participants. In 2009, MR imaging assessments were extended to all eligible BLSA participants, who also receive full cognitive assessments, with the current follow-up visit schedule: age less than 60, every 4 years, age 60-79, every 2 years, age 80 and older, every year. 3T MRI data and select variables for a small subset of the BLSA participants are available for download from LONI IDA (https://ida.loni.usc.edu/) and GAAIN (https://www.gaaindata.org/partner/BLSA). For the larger BLSA dataset, investigators can apply for data access via https://www.blsa.nih.gov/.",https://www.blsa.nih.gov/sites/default/files/2018-08/BLSA_Core_datasets_DATA-DICTIONARY__122017.pdf,/cbica/projects/BLSA,/cbica/projects/BLSA/Pipelines/rsfMRI/BLSA_fMRI_2023/Data/,893,/cbica/projects/BLSA/Pipelines/DTI/BLSA_DTI_2025/Data/,141 (140),/cbica/projects/BLSA/Pipelines/rsfMRI/BLSA_fMRI_2023/Protocols/XCP,Coming Soon,,,,,,,,,/cbica/projects/BLSA/Pipelines/MRI/BLSA_DLMUSE_2025/Results/DLMUSE_Volumes.csv,,,,,,,,,,,,,,,,,
ISTAGING,CARDIA,Coronary Artery Risk Development in Young Adults,892,487,52.8,51.2 ± 4.0,USA,1985,TRUE,Cardiovascular risk in young adults,cardiovascular,0,0,1,0,1,0,reisjp@mail.nih.gov,,https://doi.org/10.1161/JAHA.117.006750,https://biolincc.nhlbi.nih.gov/studies/cardia/,,,"The Coronary Artery Risk Development in Young Adults (CARDIA) is an ongoing longitudinal study of the development and trajectories of cardiovascular disease in a bi-racial population-based cohort. Data collection began in 1985 with follow-up visits in 5-year intervals, at four sites in the USA. Brain MRI began in CARDIA year 25 and continued in year 30 and year 35, with a subset of less than 1,000 of over 5,000 subjects participating in the brain MRI protocol. Non-imaging data from the CARDIA study is available through the NHLBI’s BIOLINCC [https://biolincc.nhlbi.nih.gov/studies/cardia/].",https://biolincc.nhlbi.nih.gov/media/studies/cardia/data_dictionary/CARDIA_2023a.pdf,/cbica/projects/cardia,,,,,/cbica/projects/cardia/Pipelines/CARDIA_fMRI_2025/Protocols/XCP,Coming Soon,,,,,,,,,/cbica/projects/cardia/Pipelines/CARDIA_DLMUSE_2025/Results/DLMUSE_Volumes.csv,,,,,,,,,,,,,,,,,
ISTAGING,FITBIR,Federal Interagency TBI Research ,1496,1845,28.5,33.3 ± 14.6,USA,2010,TRUE,Traumatic brain injury data repository,tbi,0,0,0,0,0,1,,,https://doi.org/10.1891/0739-6686.33.1,https://fitbir.nih.gov/,https://fitbir.nih.gov/content/access-data,,"The Federal Interagency TBI Research (FITBIR) informatics system is hosted in collaboration between the NIH and the UK Department of Defense, as a public dataset for research into traumatic brain injury (TBI). The consortium includes multiple studies with varying data collection procedures, all focused on TBI. Data is publicly available via [https://fitbir.nih.gov/].",,/cbica/projects/fitbir,NA,,NA,,NA,NA,,,,,,,,,/cbica/projects/fitbir/Pipelines/FITBIR_DLMUSE_2025/Results/DLMUSE_Volumes.csv,,,,,,,,,,,,,,,,,
ISTAGING,GSP,Genomics Superstruct Project,1570,0,57.6,21.5 ± 2.9,USA,2009,FALSE,Healthy brain variability and genomics,healthy_brain,1,0,0,0,1,0,,,https://www.nature.com/articles/sdata201531,https://www.neuroinfo.org/gsp,"https://ida.loni.usc.edu/collaboration/access/appApply.jsp?project=GSP

AND

https://static1.squarespace.com/static/5b58b6da7106992fb15f7d50/t/5b9be03521c67c0e1c20948d/1583778429685/GSP_Restricted_Application.pdf",,"The Brain Genomics Superstruct Project (GSP) aims to examine the link between brain function, behavior, and genetic variation. Data collection included a saliva-based genomic data collection, structural and function MR imaging, and ongoing online assessments including demographics, health questionnaires, cognitive and behavioral assessment in 1,570 young and healthy participants.",,/cbica/projects/Public_Studies,/cbica/projects/Public_Studies/GSP/Pipelines/GSP_fMRI_2025/Data,9,NA,,/cbica/projects/Public_Studies/GSP/Pipelines/GSP_fMRI_2025/Protocols/XCP,NA,,,,,,,,,/cbica/projects/Public_Studies/GSP/Pipelines/GSP_DLMUSE_2025/Results/DLMUSE_Volumes.csv,,,,,,,,,,,,,,,,,
ISTAGING,HABS-HD (HABLE),The Health & Aging Brain Study - Health Disparities,2912,1850,62.5,65.2 ± 8.7,USA,2010,TRUE,Aging in Latino elders,cognitive_aging,1,1,0,0,0,0,,,https://pmc.ncbi.nlm.nih.gov/articles/PMC8215806/#sec27,"https://ida.loni.usc.edu/home/projectPage.jsp?project=HABLE
https://apps.unthsc.edu/itr/our",,,"The Health & Aging Brain Study – Healthy Disparities (HABS-HD) is a study comprised of 1705 community-dwelling Mexican American and non-Hispanic White adults aged 50 and older. The primary goal being to enhance the representation of this population in aging and Alzheimer’s research. Subjects underwent neuropsychological testing, clinical lab measures, and obtained both MRI and amyloid and tau PET scans. Data is available via [https://apps.unthsc.edu/itr/our]",,/cbica/projects/Public_Studies,NA,,NA,,NA,NA,,,,,,,,,/cbica/projects/Public_Studies/HABLE/Pipelines/HABLE_DLMUSE_2025/Results/DLMUSE_Volumes.csv,,,,,,,,,,,,,,,,,
ISTAGING,HABS,Human Alzheimer’s Brain Study,289,224,59.2,73.8 ± 6.2,USA,2009,TRUE,Preclinical Alzheimer's aging cohort,alzheimers,1,1,0,0,0,0,,,https://doi.org/10.1016/j.neuroimage.2015.03.069,https://habs.mgh.harvard.edu/,https://www.synapse.org/Synapse:syn53910452/wiki/626438,,"The Harvard Brain Aging Study (HABS) is a longitudinal observational study of healthy and pathological aging from cognitively unimpaired participants age 65 and older. MR and PET imaging protocols were designed to be compatible with ADNI. Clinical assessments include demographics, neurocognitive and neuropsychological assessments, blood work, APOE genotyping, and physiological measurements. Data is publicly available via [https://habs.mgh.harvard.edu/researchers/].",,/cbica/projects/Public_Studies,/cbica/projects/Public_Studies/HABS/Pipelines/HABS_fMRI_2025/Data,290,/cbica/projects/Public_Studies/HABS/Pipelines/HABS_DTI_2025/Data,1046 (705),/cbica/projects/Public_Studies/HABS/Pipelines/HABS_fMRI_2025/Protocols/XCP,/cbica/projects/Public_Studies/HABS/Pipelines/HABS_DTI_2025/Protocols/,,,,,,,,,/cbica/projects/Public_Studies/HABS/Pipelines/HABS_DLMUSE_2025/Results/DLMUSE_Volumes.csv,,,,,,,,,,,,,,,,,
ISTAGING,HANDLS,Healthy Aging in Neighborhoods of Diversity Across the Life Span,233,0,54.5,52.8 ± 9.3,USA,2000,TRUE,Health disparities and aging,aging_health,1,0,1,0,1,0,,,https://doi.org/10.1097/PSY.0000000000000408,https://handls.nih.gov/,,"The Healthy Aging in Neighborhoods of Diversity Across the Life Span (HANDLS) Scan substudy was funded by NIA grants R01AG034161, P30AS028747-14S1, R56AG064088-01A1, and the NIA Intramural Research Program ZIAG000513.","The Healthy Aging in Neighborhoods of Diversity across the Life Span (HANDLS) study is an ongoing longitudinal study of race and socioeconomic-related health disparities based in Baltimore. Brain MRI was introduced in the third wave of the HANDLS protocol, between the years 2009-2013. Data availability via submitted and reviewed proposals [https://handls.nih.gov/06Coll.htm].",,/cbica/projects/handls,Coming Soon,,NA,,Coming Soon,NA,,,,,,,,,/cbica/projects/handls/Pipelines/HANDLS_DLMUSE_2025/Results/DLMUSE_Volumes.csv,,,,,,,,,,,,,,,,,
ISTAGING,HCP-Aging,Human Connectome Project – Aging,715,0,55.8,60.4 ± 15.8,USA,2017,TRUE,Lifespan connectomics,connectome_aging,1,0,0,0,1,0,,,"https://doi.org/10.1016/j.neuroimage.2018.10.009
https://doi.org/10.1016/j.neuroimage.2018.09.060",https://www.humanconnectome.org/study/hcp-lifespan-aging,,,"the HCP was later extended to cover the entire lifespan, through the HCP-Aging study, which covers ages 36-100 with high resolution MR imaging studies in over 1,200 adult participants. Data available via the NDA website via [https://nda.nih.gov/edit_collection.html?id=2847].",,/cbica/projects/Public_Studies,NA,,NA,,NA,NA,,,,,,,,,/cbica/projects/Public_Studies/HCP-Aging/Pipelines/HCP-Aging_DLMUSE_2025/Results/DLMUSE_Volumes.csv,,,,,,,,,,,,,,,,,
ISTAGING,HCP-YA,Human Connectome Project – Young Adult,1113,0,54.4,28.8 ± 3.7,USA,2010,FALSE,Young adult healthy connectome,connectome,0,0,0,0,1,0,,,https://doi.org/10.1038/nn.4361,https://www.humanconnectome.org/study/hcp-young-adult,https://www.humanconnectome.org/study/hcp-young-adult/document/quick-reference-open-access-vs-restricted-data,,"The Human Connectome Project Young Adult study (HCP-YA) aimed to create a standard map of normal connections between brain regions. Toward this goal, they collected over 1,100 high resolution MR imaging studies in healthy young adult twins and siblings. The MR imaging data is publicly available via [https://www.humanconnectome.org/study/hcp-young-adult].",,/cbica/projects/Public_Studies,/cbica/projects/Public_Studies/HCP-YA/Pipelines/HCP-YA_fMRI_2024/Data,,,,/cbica/projects/Public_Studies/HCP-YA/Pipelines/HCP-YA_fMRI_2024/Protocols/XCP,,,,,,,,,,/cbica/projects/Public_Studies/HCP-YA/Pipelines/HCP-YA_DLMUSE_2025/Results/DLMUSE_Volumes.csv,,,,,,,,,,,,,,,,,
ISTAGING,KBASE,Korean Brain Aging Study for the Early Diagnosis & Prediction of Alzheimer’s Disease,602,596,42,67.0 ± 13.4,South Korea,2010,TRUE,Alzheimers and dementia cohort,alzheimers,0,1,0,0,0,0,,,,http://kbase.kr/eng/main/index.php,,KBASE is supported by grant U01 AG072177.,"The Korean Brain Aging Study for the Early Diagnosis and Prediction of Alzheimer’s Disease (KBASE) is a longitudinal study that includes 591 participants over the lifespan (20-90 years) including 291 older controls, 74 young/middle aged controls, 139 with mild cognitive impairment, and 87 with Alzheimer’s disease. Collection included clinical and neuropsychological testing, T1w MRI and amyloid PET imaging, as well as blood and genetic markers. ",,/cbica/projects/Public_Studies,Coming Soon,,Coming Soon,,Coming Soon,Coming Soon,,,,,,,,,/cbica/projects/Public_Studies/KBASE/Pipelines/KBASE_DLMUSE_2025/Results/DLMUSE/DLMUSE_Volumes.csv,,,,,,,,,,,,,,,,,
ISTAGING,MESA,Multi-Ethnic Study of Atherosclerosis,1041,0,53.3,74.2 ± 8.2,USA,2000,TRUE,Multi-ethnic atherosclerosis study,cardiovascular,0,0,1,0,1,0,,,https://doi.org/10.1161/JAHA.121.023159,https://mesa-nhlbi.org/about/overview,"https://tools.mesa-nhlbi.org/MESA_Files/publications/Information%20for%20New%20Investigators.pdf

AND

https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?stacc=phs000283.v1.p1&view_pdf",,"The Multi‐Ethnic Study of Atherosclerosis (MESA) is a longitudinal study of subclinical cardiovascular disease that began in the year 2000. This population has diverse racial and ethnic characteristics, including 25% Black, 15% Chinese American, 19% Hispanic, and 41% White participants. The MESA cohort was sub-sampled to collect brain MR imaging at six sites at the time of the sixth exam, between the years 2018-2019.",,/cbica/projects/MESA,Coming Soon,,Coming Soon,,Coming Soon,Coming Soon,,,,,,,,,/cbica/projects/MESA/MESA-AFIB/Pipelines/MESA-AFIB_DLMUSE_2025/Results/DLMUSE_Volumes.csv,,,,,,,,,,,,,,,,,
ISTAGING,OASIS,Open Access Series of Imaging Studies,1751,1076,53.9,74.4 ± 11.0,USA,2005,TRUE,Aging and Alzheimer's neuroimaging,alzheimers,1,1,0,0,0,0,,,https://doi.org/10.1162/jocn.2007.19.9.1498,https://www.oasis-brains.org/,https://sites.wustl.edu/oasisbrains/home/access/,"Data were provided [in part] by OASIS OASIS-3: Principal Investigators: T. Benzinger, D. Marcus, J. Morris; NIH P50 AG00561, P30 NS09857781, P01 AG026276, P01 AG003991, R01 AG043434, UL1 TR000448, R01 EB009352. AA was funded through grants 191026.","OASIS-3 is a longitudinal neuroimaging, clinical, cognitive, and biomarker dataset for normal aging and Alzheimer’s Disease. OASIS-3 is a retrospective compilation of data for 1378 participants that were collected across several ongoing projects through the WUSTL Knight ADRC over the course of 30years. OASIS-4 consists of a clinical cohort who was evaluated for memory disorders and dementia. OASIS-4 is a unique dataset and not an update to the OASIS-3. The OASIS datasets hosted by central.xnat.org provide the community with open access to a significant database of neuroimaging and processed imaging data across a broad demographic, cognitive, and genetic spectrum an easily accessible platform for use in neuroimaging, clinical, and cognitive research on normal aging and cognitive decline. All data is available via [www.oasis-brains.org].",,/cbica/projects/OASIS,/cbica/projects/OASIS/OASIS3/Pipelines/OASIS3_fMRI_Sep2023/Data/Init_Downloaded/scans/All/,1198 (986),,,/cbica/projects/OASIS/OASIS3/Pipelines/OASIS3_fMRI_Sep2023/Protocols/XCP/,Coming Soon,OASIS3=42-95;OASIS4=21-94,OASIS3=1379;OASIS4=663,OASIS3=2842;OASIS4=676,Yes,Yes,Yes,Yes,No,OASIS3=/cbica/projects/OASIS/OASIS3/Pipelines/OASIS3_DLMUSE_2025/Results/DLMUSE_Volumes.csv;OASIS4=/cbica/projects/OASIS/OASIS4/Pipelines/OASIS4_DLMUSE_2025/Results/DLMUSE_Volumes.csv,OASIS3=version ???;OASIS4=version ???,OASIS3=2162;OASIS4=671,OASIS3=/cbica/projects/OASIS/OASIS3/Pipelines/OASIS3_DLWMLS_2025/Results/OASIS3_DLWMLS_DLMUSE_Segmented_Volumes.csv,OASIS3=version ???,OASIS3=736,OASIS3=/cbica/projects/OASIS/OASIS3/Pipelines/OASIS3_fMRI_Sep2023/Protocols,OASIS3=23.1.3,OASIS3=2406,"OASIS3=/opt/conda/envs/fmriprep/bin/fmriprep \
  /cbica/home/srinivad/Projects/2023_OASIS_BIDS/Data/Init_Downloaded/scans/All/batch_<batch_number>/ \
  /cbica/home/srinivad/Projects/2023_OASIS_BIDS/Protocols/ \
  participant \
  --participant_label <subid> \
  --fs-license-file /cbica/home/srinivad/Projects/2023_OASIS_BIDS/license.txt \
  --fs-no-reconall \
  --output-spaces MNI152NLin2009cAsym:res-2 \
  --bids-filter-file /cbica/home/srinivad/Projects/2023_OASIS_BIDS/bids_filter.json \
  --debug all",OASIS3=/cbica/projects/OASIS/OASIS3/Pipelines/OASIS3_fMRI_Sep2023/Protocols/XCP,OASIS3=0.7.1rc6,OASIS3=1789,"OASIS3=/usr/local/miniconda/bin/xcp_d \
  /cbica/home/srinivad/Projects/2023_OASIS_BIDS/Protocols/batch_<batch_number> \
  /cbica/home/srinivad/Projects/2023_OASIS_BIDS/Protocols/XCP/batch_<batch_number> \
  participant \
  --participant_label <subid> \
  --bids-filter-file /cbica/home/srinivad/Projects/2023_OASIS_BIDS/bids_filter.json \
  --input-type fmriprep \
  -p 36P \
  --work-dir /cbica/home/srinivad/Projects/2023_OASIS_BIDS/ \
  --motion-filter-type lp \
  --band-stop-min 6 \
  --motion-filter-order 4 \
  --despike \
  --fd-thresh 0 \
  --lower-bpf 0.01 \
  --upper-bpf 0.08 \
  --bpf-order 2 \
  --head-radius auto \
  --dummy-scans auto \
  --min-coverage 0.5 \
  --smoothing 0 \
  --fs-license-file /cbica/home/srinivad/Projects/2023_OASIS_BIDS/license.txt",Added to website. TODO: Fill in the ???. Add any missing pipelines,,,
ISTAGING,PENN,University of Pennsylvania (PENN) Study,1031,187,56.6,72.9 ± 9.3,USA,NA,TRUE,Memory and Alzheimers research,alzheimers,0,1,0,0,0,0,,,https://doi.org/10.1136/jnnp-2012-302548,https://pennmemorycenter.org/,,,"The PENN dataset was collected at the University of Pennsylvania’s Memory Center, including participants with memory complaints and early stages of cognitive decline. Data collection is compatible with the standard National Alzheimer’s Coordinating Center’s uniform data set.",,/cbica/projects/chrisclark,Coming Soon,,NA,,Coming Soon,NA,,,,,,,,,/cbica/projects/chrisclark/ADC/Pipelines/ABC_DLMUSE_2025/Results/DLMUSE_Volumes.csv;/cbica/projects/chrisclark/ADC/Pipelines/PMC_DLMUSE_2025/Results/DLMUSE_Volumes.csv,,,,,,,,,,,,,,,,,
ISTAGING,PreventAD,Prevention of Alzheimer’s Disease,343,870,70.8,63.6 ± 5.0,Canada,2010,TRUE,Alzheimers prevention cohort,alzheimers,0,1,0,0,0,0,,,https://doi.org/10.1016/j.nicl.2021.102733,https://openpreventad.loris.ca/,,"The PREVENT-AD study was funded through McGill University, the FRQ-S, the CIHR, Pfizer Canada, Brain Canada, the Alzheimer’s Society of Canada, the Canada Fund for Innovation, the J.L. Levesque Foundation, and the Lemaire Foundation.","The Pre-symptomatic Evaluation of Experimental or Novel Treatments for AD (PREVENT-AD) is an observational study of cognitively unimpaired participants with a sibling or family member who has or had Alzheimer’s disease. N= 349 study participants were enrolled at McGill University from the year 2010, some of whom participated in a clinical trial for an anti-inflammatory drug, naproxen sodium. Data collection includes longitudinal MR imaging, CSF biomarker and genetic assays, and cognitive and health screenings. Data is publicly available via [https://openpreventad.loris.ca/].",,/cbica/projects/Prevent_AD,/cbica/projects/Prevent_AD/Pipelines/PreventAD_fMRI_2024/Data/,306 (753),NA,340 (449),/cbica/projects/Prevent_AD/Pipelines/PreventAD_fMRI_2024/Protocols/XCP/,NA,,,,,,,,,/cbica/projects/Prevent_AD/Pipelines/PreventAD_DLMUSE_2025/Results/DLMUSE/DLMUSE_Volumes.csv,,,,,,,,,,,,,,,,,
ISTAGING,SHIP,Study of Health in Pomerania,3311,0,51.3,52.8 ± 13.8,Germany,1997,TRUE,Population health and epidemiology,epidemiology,0,0,1,0,1,0,,,"https://doi.org/10.3174/ajnr.A4805
https://doi.org/10.1055/s-0028-1109510",https://www2.medizin.uni-greifswald.de/cm/fv/ship.html,,"The Study of Health in Pomerania (SHIP) is part of the Community Medicine Research net (CMR) (http://www.medizin.uni-greifswald.de/icm) of the University Medicine Greifswald, which is supported by the German Federal State of Mecklenburg- West Pomerania. MRI scans in SHIP and SHIP-TREND have been supported by a joint grant from Siemens Healthineers, Erlangen, Germany and the Federal State of Mecklenburg-West Pomerania.","The Study of Health in Pomerania (SHIP) is a population-based cohort including adults from 22-90 years old with MR imaging collected from 2008-2012. Additional data collection includes demographics, health history, cognitive testing, and genotyping.",,/cbica/projects/Greifswald,NA,,NA,,NA,NA,,,,,,,,,/cbica/projects/Greifswald/Pipelines/SHIP_DLMUSE_2025/Results/DLMUSE_Volumes.csv,,,,,,,,,,,,,,,,,
ISTAGING,SPRINT,Systolic Blood Pressure Intervention Trial,785,547,38.9,68.0 ± 8.6,USA,2010,FALSE,Blood pressure management trial,hypertension,0,0,1,0,0,0,,,https://jamanetwork.com/journals/jama/fullarticle/2747671,https://biolincc.nhlbi.nih.gov/studies/sprint/,https://biolincc.nhlbi.nih.gov/studies/sprint,,"The Systolic Blood Pressure Intervention Trial (SPRINT) is a randomized control trial designed to evaluate how intensive blood pressure treatment affects the cardiovascular system, kidneys, and brain. The clinical trial ran from 2010-2015, including brain MR imaging in a subset of N= 670 participants. MR data was collected at seven sites according to a standardized protocol. Non-imaging data from the SPRINT clinical trial is available through the NHLBI’s BIOLINCC [https://biolincc.nhlbi.nih.gov/studies/sprint/].",,/cbica/projects/sprint,Coming Soon,,Coming Soon,,Coming Soon,Coming Soon,,,,,,,,,/cbica/projects/sprint/Pipelines/SPRINT_DLMUSE_2025/Results/DLMUSE_Volumes.csv,,,,,,,,,,,,,,,,,
ISTAGING,UKBIOBANK,UK Biobank,39576,1408,52.9,64.1 ± 7.5,UK,2006,TRUE,Large-scale population biobank,multi_disease,0,0,1,0,1,0,,,https://doi.org/10.1016/j.neuroimage.2017.10.034,https://www.ukbiobank.ac.uk/,https://www.ukbiobank.ac.uk/use-our-data/apply-for-access/,,"The UK Biobank is a major national and international health resource, and a registered charity in its own right, with the aim of improving the prevention, diagnosis and treatment of a wide range of serious and life-threatening illnesses – including cancer, heart diseases, stroke, diabetes, arthritis, osteoporosis, eye disorders, depression and forms of dementia. UK Biobank recruited 500,000 people aged between 40-69 years in 2006-2010 from across the country to take part in this project. They have undergone measures, provided blood, urine and saliva samples for future analysis, detailed information about themselves and agreed to have their health followed. Over many years this will build into a powerful resource to help scientists discover why some people develop a disease and others do not. The UK Biobank dataset is publicly available for researchers via [https://www.UK Biobank.ac.uk/].",,/cbica/projects/UKBB_Processed,NA,2364,/cbica/projects/UKBB_Processed/Pipelines/UKBB_fMRI_2024/Protocols/XCP_D/,,NA,/cbica/projects/UKBB_Processed/Pipelines/UKBB_DTI_2024/Protocols/Batch_0/qsirecon/,,,,,,,,,/cbica/projects/UKBB_Processed/Pipelines/UKBB_DLMUSE_2025/Results/DLMUSE_Volumes.csv,,,,,,,,,,,,,,,,,
ISTAGING,WHIMS,Women’s Health Initiative Memory Study,1418,727,100,69.6 ± 3.6,USA,1996,TRUE,Women's cognitive aging and menopause,alzheimers,1,1,0,0,0,0,,,https://doi.org/10.1212/01.wnl.0000339037.76336.cf,https://www.whi.org/md/39/whi-memory-study-whims,https://www.whi.org/md/DUA,,"Brain MRI scans were obtained in a subset of 1,403 women aged 71–89 years who participated in the Women’s Health Initiative Memory Study (WHIMS). WHIMS is an ancillary study to the Women’s Health Initiative, which consisted of two randomized, placebo-controlled trials: 0.625 mg conjugated equine estrogens (CEE) with or without 2.5 mg medroxyprogesterone acetate (MPA) in one daily tablet. Scans were performed, on average, 3.0 years post-trial for the CEE + MPA trial and 1.4 years post-trial for the CEE-Alone trial; average on-trial follow-up intervals were 4.0 years for CEE + MPA and 5.6 years for CEE-Alone.",,/cbica/projects/whims,NA,,NA,,NA,NA,,,,,,,,,/cbica/projects/whims/Pipelines/WHIMS_DLMUSE_2025/Results/DLMUSE_Volumes.csv,,,,,,,,,,,,,,,,,
ISTAGING,WRAP,Wisconsin Registry for Alzheimer’s Prevention,272,463,71.3,61.7 ± 6.2,USA,2001,TRUE,Alzheimer's risk in middle-aged adults,alzheimers,1,1,0,0,0,0,,,https://doi.org/10.1016/j.dadm.2017.11.007,https://wrap.wisc.edu/about/,https://redcap.medicine.wisc.edu/surveys/?s=T9XK8EEN3Y,"The WRAP study was supported by R01 AG027161 and R01 AG021155. This study was supported in part by the National Institutes of Health (NIH) grant numbers 5R01AG080821, 1R01AG085571 and 5R01AG083865.","The Wisconsin Registry for Alzheimer’s Prevention (WRAP) is a longitudinal observational study of cognitively unimpaired adults. Participants are primarily the healthy children of late-onset Alzheimer’s Disease patients at the Memory Assessment Clinic at the University of Wisconsin-Madison. Since 2001, WRAP has followed 1,561 subjects at bi-annual assessments, including molecular PET and structural MR imaging, CSF collection, laboratory tests, genetic screening, cognitive testing, and self-reported histories of lifestyle and health.",,/cbica/projects/PreclinicalAD,NA,,NA,,NA,NA,,,,,,,,,/cbica/projects/PreclinicalAD/PAC_Studies/WRAP/Pipelines/WRAP_DLMUSE_2025/Results/DLMUSE_Volumes.csv,,,,,,,,,,,,,,,,,
ISTAGING,lookAHEAD,Action for Health in Diabetes Study (Look AHEAD),311,0,71.1,68.4 ± 6.5,USA,2001,FALSE,Diabetes weight loss trial,diabetes,0,0,1,0,0,0,,,https://doi.org/10.1093/gerona/glz090,"https://clinicaltrials.gov/study/NCT00017953
https://www.lookaheadtrial.org/",https://repository.niddk.nih.gov/pages/for_requestors,,"The Action for Health in Diabetes (LookAHEAD) trial studies the long-term effect of intensive lifestyle intervention in participants with type 2 diabetes, with outcomes of cardiovascular morbidity and mortality. The randomized control trial began in 2001 with brain MRI added in a subset of the initial trial population on average 10 years after randomization. Data from the randomized controlled clinical trial is available (including measures of brain structure and cognitive function) through the NIH’s NIDDK central repository [https://repository.niddk.nih.gov/studies/look-ahead/].",,/cbica/projects/LookAhead,NA,,NA,,NA,NA,,,,,,,,,/cbica/projects/LookAhead/Pipelines/LookAhead_DLMUSE_2025/Results/DLMUSE_Volumes.csv,,,,,,,,,,,,,,,,,
ADSP,MAP - Rush,Memory & Aging Project – Rush Alzheimer’s Disease Center,783,1103,75.7,80.6 ± 7.3,USA,1997,TRUE,Memory and aging project,alzheimers,1,1,0,0,0,0,,,https://pmc.ncbi.nlm.nih.gov/articles/PMC6380522/,https://www.rushu.rush.edu/research-rush-university/departmental-research/rush-alzheimers-disease-center/rush-alzheimers-disease-center-research/epidemiologic-research/memory-aging-project,https://www.radc.rush.edu/requests.htm,,"The Rush Memory and Aging Project is a longitudinal, clinical-pathologic cohort started in 1997 and enrolls older adults without dementia for annual clinical and cognitive evaluations. The study includes follow-up and autopsy data. Initial data collection included cognitive testing, pulmonary function, life course risk factors, and in later waves T1w MRI, resting state fMRI, post-mortem imaging, and neuropathologic assessments were integrated.",,/cbica/projects/NIAGADS,NA,,NA,,NA,NA,,,,,,,,,/cbica/projects/NIAGADS/ROSMAPMARS/Pipelines/ROSMAPMARS_DLMUSE_2025/Results/DLMUSE_Volumes.csv,,,,,,,,,,,,,,,,,
ADSP,MARS,Minority Aging Research Study,212,188,82.5,76.3 ± 6.4,USA,NA,TRUE,Alzheimers cohort (if Rush MARS),alzheimers,0,1,0,0,0,0,,,https://pmc.ncbi.nlm.nih.gov/articles/PMC3409294/,https://www.rushu.rush.edu/research-rush-university/departmental-research/rush-alzheimers-disease-center/rush-alzheimers-disease-center-research/epidemiologic-research/minority-aging-research-study,https://www.radc.rush.edu/requests.htm,,The Minority Aging Research Study (MARS) is a longitudinal cohort examining brain aging and Alzheimer’s disease in older African Americans. The study enrolls participants without dementia and tracks cognitive decline over time. Some participants may choose to donate their brain tissue for further post-mortem examination.,,/cbica/projects/NIAGADS,NA,,NA,,NA,NA,,,,,,,,,/cbica/projects/NIAGADS/ROSMAPMARS/Pipelines/ROSMAPMARS_DLMUSE_2025/Results/DLMUSE_Volumes.csv,,,,,,,,,,,,,,,,,
ADSP,WASHU,,,,,,,,,,alzheimers,,,,,,,,,,https://knightadrc.wustl.edu/professionals-clinicians/request-center-resources/guidelines-data-available/,https://knightadrc.wustl.edu/data-request-form/,,,,/cbica/projects/NIAGADS,NA,,NA,,NA,NA,,,,,,,,,/cbica/projects/NIAGADS/WASHU/Pipelines/WASHU_DLMUSE_2025/Results/DLMUSE_Volumes.csv,,,,,,,,,,,,,,,,,
ADSP,NACC,National Alzheimer’s Coordinating Center,6908,2304,58.7,71.3 ± 10.2,USA,1999,TRUE,National AD data coordinating center,alzheimers,0,1,0,0,0,1,,,,https://naccdata.org/,https://naccdata.org/requesting-data/submit-data-request,"The NACC database is funded by NIA/NIH Grant U24 AG072122. NACC data are contributed by the NIA-funded ADRCs: P30 AG062429 (PI James Brewer, MD, PhD), P30 AG066468 (PI Oscar Lopez, MD), P30 AG062421 (PI Bradley Hyman, MD, PhD), P30 AG066509 (PI Thomas Grabowski, MD), P30 AG066514 (PI Mary Sano, PhD), P30 AG066530 (PI Helena Chui, MD), P30 AG066507 (PI Marilyn Albert, PhD), P30 AG066444 (PI David Holtzman, MD), P30 AG066518 (PI Lisa Silbert, MD, MCR), P30 AG066512 (PI Thomas Wisniewski, MD), P30 AG066462 (PI Scott Small, MD), P30 AG072979 (PI David Wolk, MD), P30 AG072972 (PI Charles DeCarli, MD), P30 AG072976 (PI Andrew Saykin, PsyD), P30 AG072975 (PI Julie A. Schneider, MD, MS), P30 AG072978 (PI Ann McKee, MD), P30 AG072977 (PI Robert Vassar, PhD), P30 AG066519 (PI Frank LaFerla, PhD), P30 AG062677 (PI Ronald Petersen, MD, PhD), P30 AG079280 (PI Jessica Langbaum, PhD), P30 AG062422 (PI Gil Rabinovici, MD), P30 AG066511 (PI Allan Levey, MD, PhD), P30 AG072946 (PI Linda Van Eldik, PhD), P30 AG062715 (PI Sanjay Asthana, MD, FRCP), P30 AG072973 (PI Russell Swerdlow, MD), P30 AG066506 (PI Glenn Smith, PhD, ABPP), P30 AG066508 (PI Stephen Strittmatter, MD, PhD), P30 AG066515 (PI Victor Henderson, MD, MS), P30 AG072947 (PI Suzanne Craft, PhD), P30 AG072931 (PI Henry Paulson, MD, PhD), P30 AG066546 (PI Sudha Seshadri, MD), P30 AG086401 (PI Erik Roberson, MD, PhD), P30 AG086404 (PI Gary Rosenberg, MD), P20 AG068082 (PI Angela Jefferson, PhD), P30 AG072958 (PI Heather Whitson, MD), P30 AG072959 (PI James Leverenz, MD).","The National Alzheimer’s Coordinating Center (NACC) is the central repository for data collected from several Alzheimer’s Disease Research Centers (ADRCs) across the US. Since 2005, the center has aggregated longitudinal clinical, cognitive, demographic, and diagnostic data using its Uniform Data Set (UDS). Imaging and biomarker data are integrated using the SCAN protocol and includes MRI and PET data. The neuropathology dataset includes aspects of vascular pathology, TDP-43, Lewy bodies, and other comorbid pathologies.",,/cbica/projects/NIAGADS,NA,,NA,,NA,NA,,,,,,,,,/cbica/projects/NIAGADS/ADSP/Pipelines/ADSP_NACC_Release_V1_DLMUSE_2025/Results/DLMUSE_Volumes.csv,,,,,,,,,,,,,,,,,
ADSP,ROS,Religious Orders Study,85,74,85.9,78.9 ± 6.3,USA,1994,TRUE,Religious Orders Study on aging,alzheimers,1,1,0,0,0,0,,,https://pmc.ncbi.nlm.nih.gov/articles/PMC6380522/,https://www.rushu.rush.edu/research-rush-university/departmental-research/rush-alzheimers-disease-center/rush-alzheimers-disease-center-research/epidemiologic-research/religious-orders-study,https://www.radc.rush.edu/requests.htm,,"The ROS-MAP study includes both the Religious Orders Study (ROS), started in 1994 enrolling Catholic priests, nuns, and brothers from the US without known dementia, and the Memory and Aging Project (MAP), started in 1997 and enrolled community-dwelling older adults. Both studies include cognitive testing, clinical evaluation, and neuropathologic examination for amyloid, tau, infarcts, and Lewy bodies. More recently, the study has been extended to examine multi-omic analyses.",,/cbica/projects/NIAGADS,NA,,NA,,NA,NA,,,,,,,,,/cbica/projects/NIAGADS/ROSMAPMARS/Pipelines/ROSMAPMARS_DLMUSE_2025/Results/DLMUSE_Volumes.csv,,,,,,,,,,,,,,,,,
ADSP,WHICAP,Washington Heights–Inwood Columbia Aging Project,993,314,60.8,75.1 ± 6.4,USA,1992,TRUE,Aging and dementia in diverse populations,alzheimers,1,1,0,0,0,0,,,,https://www.maelstrom-research.org/study/whicap,https://cumc.co1.qualtrics.com/jfe/form/SV_6x5rRy14B6vpoqN,,"The Washington Heights-Inwood Columbia Aging Project (WHICAP) examines a large and diverse sample of white, black, and Hispanic participants to identify risk factors and biomarkers for understanding aging and Alzheimer’s disease.",,/cbica/projects/NIAGADS,NA,,NA,,NA,NA,,,,,,,,,/cbica/projects/NIAGADS/WHICAP/Pipelines/WHICAP_DLMUSE_2025/Results/DLMUSE_Volumes.csv,,,,,,,,,,,,,,,,,
Coordinate-MDD,BlameMRI-DePredict,NA,165,0,68.5,32.6 ± 12.3,NA,NA,NA,NA,depression,0,0,0,0,0,,,,https://pubmed.ncbi.nlm.nih.gov/39187625/,,,,,,/cbica/projects/MultisiteMD,/cbica/projects/MultisiteMD/CoordinateMD_Studies/BlameMRI-DePredict/Pipelines/BlameMRI-DePredict_fMRI_2024/Data/,102,NA,,/cbica/projects/MultisiteMD/CoordinateMD_Studies/BlameMRI-DePredict/Pipelines/BlameMRI-DePredict_fMRI_2024/Protocols/XCP/,NA,,,,,,,,,/cbica/projects/MultisiteMD/Pipelines/MultisiteMD_DLMUSE_2025/BlameMRI-DePredict/Results/BlameMRI-DePredict_DLMUSE_Volumes.csv,,,,,,,,,,,,,,,,,
Coordinate-MDD,CANBIND,Canadian Biomarker Integration Network in Depression,306,0,64.1,34.2 ± 12.0,Canada,2010,TRUE,Depression treatment response,depression,0,0,0,1,0,0,,,https://pmc.ncbi.nlm.nih.gov/articles/PMC6606427/,https://clinicaltrials.gov/study/NCT04162522,https://indocconsortium.atlassian.net/wiki/spaces/JSDNXT/pages/3015804901/CAN-BIND+Baseline+Data+Release+Dashboard+-+Data+Request+Walkthrough+Guide,,"The Canadian Biomarker Integration Network in Depression (CAN-BIND), funded by the Ontario Brain Institute, involves an 8-week treatment protocol of the selective serotonin reuptake inhibitor (SSRI) escitalopram, followed with 8-weeks of aripiprazole (if inadequate treatment response, <50% depressive symptom reduction). Scans were obtained at baseline, two weeks, and eight weeks for both the healthy participants those with major depressive disorder (MDD).",,/cbica/projects/MultisiteMD,/cbica/projects/MultisiteMD/CoordinateMD_Studies/CANBIND/Pipelines/CANBIND_fMRI_2024/Data/,83 (184),NA,,/cbica/projects/MultisiteMD/CoordinateMD_Studies/CANBIND/Pipelines/CANBIND_fMRI_2024/Protocols/XCP/,NA,,,,,,,,,/cbica/projects/MultisiteMD/Pipelines/MultisiteMD_DLMUSE_2025/CANBIND/Results/CANBIND_DLMUSE_Volumes.csv,,,,,,,,,,,,,,,,,
Coordinate-MDD,COBY,Course and Outcome of Bipolar Youth ,92,0,54.3,25.0 ± 4.3,NA,NA,NA,NA,bipolar,0,0,0,0,0,,,,https://jamanetwork.com/journals/jamapsychiatry/fullarticle/209320,https://pre.pediatricbipolar.pitt.edu/coby-study,,,"The Course and Outcome of Bipolar Youth (COBY) study followed 413 children and adolescents (ages 7–17) diagnosed with bipolar I (n=244), bipolar II (n=28), or bipolar not otherwise specified (NOS) (n=141), recruited largely from outpatient clinics at Pittsburgh, Brown, and UCLA. Clinical symptoms were tracked retrospectively with the Longitudinal Interval Follow-up Evaluation about every 9 months over a 4-year period. The primary analyses focused on recovery rates, recurrence, and detailed week-by-week symptomatic course.",,/cbica/projects/MultisiteMD,NA,,NA,,NA,NA,,,,,,,,,/cbica/projects/MultisiteMD/Pipelines/MultisiteMD_DLMUSE_2025/COBY/Results/COBY_DLMUSE_Volumes.csv,,,,,,,,,,,,,,,,,
Coordinate-MDD,DIAMOND,NA,222,0,68.5,22.8 ± 3.3,NA,NA,NA,NA,bipolar,0,0,0,0,0,,,,https://implementationscience.biomedcentral.com/articles/10.1186/1748-5908-8-135,https://archive.thepcc.org/initiative/diamond-initiative,,,The DIAMOND study is a population of 253 young adults (aged 18-25) with and without bipolar disorder from the University of Pittsburgh.,,/cbica/projects/MultisiteMD,NA,,NA,,NA,NA,,,,,,,,,/cbica/projects/MultisiteMD/Pipelines/MultisiteMD_DLMUSE_2025/DIAMOND/Results/DIAMOND_DLMUSE_Volumes.csv,,,,,,,,,,,,,,,,,
Coordinate-MDD,EMBARC,Establishing Moderators and Biosignatures of Antidepressant Response in Clinical Care,,,,,,,,,depression,,,,,,,,,https://www.sciencedirect.com/science/article/pii/S0022395616300395,https://osf.io/79cwy/overview,NDA DUC - https://nda.nih.gov/edit_collection.html?id=2199,,The Establishing Moderators and Biosignatures of Antidepressant Response in Clinical Care (EMBARC) is a multisite randomized placebo-control clinical trial consisting of two stages of double-blind treatment. Stage 1 participants were randomized to receive placebo or sertraline for eight weeks. Stage 2 continued for eight weeks if participants display meaningful improvement on the Clinical Global Improvement (CGI) scale. Those with minimal improvement transitioned to bupropion. MRI scans were obtained at baseline in both medication-free individuals and those with MDD and healthy controls.,,/cbica/projects/MultisiteMD,/cbica/projects/MultisiteMD/CoordinateMD_Studies/EMBARC/Pipelines/EMBARC_fMRI_2024/Data/,185 (144),NA,,/cbica/projects/MultisiteMD/CoordinateMD_Studies/EMBARC/Pipelines/EMBARC_fMRI_2024/Protocols/XCP/,NA,,,,,,,,,/cbica/projects/MultisiteMD/Pipelines/MultisiteMD_DLMUSE_2025/EMBARC/Results/EMBARC_DLMUSE_Volumes.csv,,,,,,,,,,,,,,,,,
Coordinate-MDD,KCL,King’s College London Study,40,0,90,29.8 ± 6.6,UK,NA,NA,Kings College London cohort,depression,0,0,0,0,1,0,,,https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2727131,,,,"The Kings College London is comprised of four studies and involves an eight week treatment protocol of the serotonin-norepinephrine reuptake inhibitors (SNRI) duloxetine. MRI was obtained at baseline, and weeks two and eight for both those with MDD and healthy participants.",,/cbica/projects/MultisiteMD,NA,,NA,,NA,NA,,,,,,,,,/cbica/projects/MultisiteMD/Pipelines/MultisiteMD_DLMUSE_2025/KCL-BUD/Results/KCL-BUD_DLMUSE_Volumes.csv,,,,,,,,,,,,,,,,,
Coordinate-MDD,LIBR,Longitudinal Imaging of Brain & Risk Study,292,0,62.7,32.0 ± 10.5,NA,NA,NA,NA,depression,0,0,0,0,0,,,,https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2727131,,,,The Laureate Institute for Brain Research (LIBR) is combined of two studies of those with first episode and recurrent major depressive disorder (MDD) and matched controls.,,/cbica/projects/MultisiteMD,"/cbica/projects/MultisiteMD/CoordinateMD_Studies/LIBR-BodurkaR01/Pipelines/LIBR-BodurkaR01_fMRI_2024/Data/
/cbica/projects/MultisiteMD/CoordinateMD_Studies/LIBR-SvitzK01/Pipelines/LIBR-SvitzK01_fMRI_2024/Data/",175; 121,NA,,"/cbica/projects/MultisiteMD/CoordinateMD_Studies/LIBR-BodurkaR01/Pipelines/LIBR-BodurkaR01_fMRI_2024/Protocols/XCP/
/cbica/projects/MultisiteMD/CoordinateMD_Studies/LIBR-SvitzK01/Pipelines/LIBR-SvitzK01_fMRI_2024/Protocols/XCP/",NA,,,,,,,,,/cbica/projects/MultisiteMD/Pipelines/MultisiteMD_DLMUSE_2025/LIBR-BodurkaR01/Results/LIBR-BodurkaR01_DLMUSE_Volumes.csv;/cbica/projects/MultisiteMD/Pipelines/MultisiteMD_DLMUSE_2025/LIBR-SvitzK01/Results/LIBR-SvitzK01_DLMUSE_Volumes.csv,,,,,,,,,,,,,,,,,
Coordinate-MDD,Manchester,Manchester Brain Imaging Study,70,0,68.6,35.1 ± 8.9,UK,NA,NA,University of Manchester cohorts,depression,0,0,0,0,1,0,,,,,,,The University of Manchester cohort combines three smaller cohorts and includes an eight-week trial of the SSRI citalopram and included MRI scans at baseline for both those with major depressive disorder and healthy controls.,,/cbica/projects/MultisiteMD,/cbica/projects/MultisiteMD/CoordinateMD_Studies/Manchester-Remedi/Pipelines/Manchester-Remedi_fMRI_2024/Data/,70 (70),,,/cbica/projects/MultisiteMD/CoordinateMD_Studies/Manchester-Remedi/Pipelines/Manchester-Remedi_fMRI_2024/Protocols/XCP/,,,,,,,,,,/cbica/projects/MultisiteMD/Pipelines/MultisiteMD_DLMUSE_2025/Manchester-Remedi/Results/Manchester-Remedi_DLMUSE_Volumes.csv,,,,,,,,,,,,,,,,,
Coordinate-MDD,PReDICT,Prediction of Depression Risk in Clinical Treatment,122,0,53.3,38.6 ± 10.9,USA,2010,FALSE,Depression treatment prediction,depression,0,0,0,1,0,0,,,https://pubmed.ncbi.nlm.nih.gov/36690972/,,,,"Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) is a 12-week randomized clinical trial for treatment-naïve major depressive disorder (MDD). Participants fall into one of three treatment arms including escitalopram, duloxetine, or cognitive behavioral therapy (CBT). If remission is not achieved, the participant undergoes a second phase of monotherapy. CBT is added to for the users in the escitalopram or duloxetine arms, or escitalopram is added for those in the CBT arm. MRI is obtained at baseline and week 12.",,/cbica/projects/MultisiteMD,NA,,NA,,NA,NA,,,,,,,,,/cbica/projects/MultisiteMD/Pipelines/MultisiteMD_DLMUSE_2025/PReDICT/Results/PReDICT_DLMUSE_Volumes.csv,,,,,,,,,,,,,,,,,
Coordinate-MDD,HMRRC (SCU),Human Memory & Research Resource Center (SCU),269,0,56.1,31.4 ± 11.4,NA,NA,NA,NA,depression,0,0,0,0,0,,,,https://cdnsciencepub.com/doi/10.1503/jpn.170112,,,,The Huaxi MR Research Center (HMRRC) cohort is comprised of first episode MDD medication-naïve and matched control. All participants receive baseline MRI scans.,,/cbica/projects/MultisiteMD,"/cbica/projects/MultisiteMD/CoordinateMD_Studies/SCU-Set1/Pipelines/SCU-Set1_fMRI_2024/Data/
/cbica/projects/MultisiteMD/CoordinateMD_Studies/SCU-Set2/Pipelines/SCU-Set2_fMRI_2024/Data/",70; 199,NA,,"/cbica/projects/MultisiteMD/CoordinateMD_Studies/SCU-Set2/Pipelines/SCU-Set2_fMRI_2024/Protocols/XCP/
/cbica/projects/MultisiteMD/CoordinateMD_Studies/SCU-Set1/Pipelines/SCU-Set1_fMRI_2024/Protocols/XCP/",NA,,,,,,,,,/cbica/projects/MultisiteMD/Pipelines/MultisiteMD_DLMUSE_2025/SCU-Set1/Results/SCU-Set1_DLMUSE_Volumes.csv;/cbica/projects/MultisiteMD/Pipelines/MultisiteMD_DLMUSE_2025/SCU-Set2/Results/SCU-Set2_DLMUSE_Volumes.csv,,,,,,,,,,,,,,,,,
Coordinate-MDD,Standford (SNAP),Data from the Stanford Neurodevelopment Affect and Pyschopathology Laboratory,110,0,64.5,32.6 ± 11.2,USA,NA,NA,Stanford Alzheimer or aging cohort,alzheimers,1,1,0,0,0,0,,,,,,,,,/cbica/projects/MultisiteMD,/cbica/projects/MultisiteMD/CoordinateMD_Studies/SNAP/Pipelines/SNAP_fMRI_2024/Data/,110,NA,,/cbica/projects/MultisiteMD/CoordinateMD_Studies/SNAP/Pipelines/SNAP_fMRI_2024/Protocols/XCP/,NA,,,,,,,,,/cbica/projects/MultisiteMD/Pipelines/MultisiteMD_DLMUSE_2025/SNAP/Results/SNAP_DLMUSE_Volumes.csv,,,,,,,,,,,,,,,,,
Coordinate-MDD,STRADL,STratifying Resilience and Depression Longitudinally (STRADL,,,,,,,,,,,,,,,,,,https://pubmed.ncbi.nlm.nih.gov/35237729/,https://wellcomeopenresearch.org/articles/4-185,,,,,/cbica/projects/MultisiteMD,/cbica/projects/MultisiteMD/CoordinateMD_Studies/STRADL/Pipelines/STRADL_fMRI_2024/Data/,1082,NA,,/cbica/projects/MultisiteMD/CoordinateMD_Studies/STRADL/Pipelines/STRADL_fMRI_2024/Protocols/XCP/,NA,,,,,,,,,/cbica/projects/MultisiteMD/Pipelines/MultisiteMD_DLMUSE_2025/STRADL/Results/STRADL_DLMUSE_Volumes.csv,,,,,,,,,,,,,,,,,
Coordinate-MDD,iSPOT-D,International Study to Predict Optimized Treatment in Depression,200,0,51.5,34.5 ± 12.2,Australia,2010,FALSE,Depression treatment prediction,depression,0,0,0,1,0,0,,,https://pubmed.ncbi.nlm.nih.gov/21208417/,https://www.stanfordpmhw.com/ispot-d,https://redcap.link/pmhw_analysis_request,,"The International Study to Predict Optimized Treatment for Depression (iSPOT-D) is a large, multi-center randomized clinical trial aimed to identify baseline predictors and moderators of treatment response for MDD. Outpatients (aged 18-65) with MDD were enrolled to escitalopram, sertraline, or venlafaxine. MDD participants and matched healthy controls underwent baseline assessment, cognitive testing, and some underwent imaging. An additional subset of individuals underwent a repeat of these assessments at week eight.",,/cbica/projects/MultisiteMD,NA,,NA,,NA,NA,,,,,,,,,/cbica/projects/MultisiteMD/Pipelines/MultisiteMD_DLMUSE_2025/Stanford_iSPOTD/Results/Stanford_iSPOTD_DLMUSE_Volumes.csv,,,,,,,,,,,,,,,,,
PHENOM,ABIDE,Autism Brain Imaging Data Exchange,,,,,,,,Imaging data for autism spectrum disorder,autism,,,,,,,,,,"https://fcon_1000.projects.nitrc.org/indi/abide/
https://datacatalog.med.nyu.edu/dataset/10452","ABIDE I: https://fcon_1000.projects.nitrc.org/indi/abide/abide_I.html
ABIDE II: https://fcon_1000.projects.nitrc.org/indi/abide/abide_II.html",,,,/cbica/projects/PsychAnalysis,NA,,NA,,NA,NA,,,,,,,,,/cbica/projects/PsychAnalysis/Pipelines/PHENOM_DLMUSE_2025/ABIDE/Results/ABIDE_DLMUSE_Volumes.csv,,,,,,,,,,,,,,,,,
PHENOM,China-Peking-Unv,Psychosis data from China Peking University,67,0,43.3,23.4 ± 4.3,China,NA,NA,Chinese university cohort,NA,0,0,0,0,1,0,,,https://pubmed.ncbi.nlm.nih.gov/27651212/,,,"The PHENOM study is funded by NIA grant R01MH112070 and by the PRONIA project as funded by the European Union 7th Framework Program grant 602152. Other supporting funds are 5U01AG068057, 1U24AG074855, R01MH119219 and S10OD023495.",,,/cbica/projects/PsychAnalysis,NA,,NA,,NA,NA,,,,,,,,,/cbica/projects/PsychAnalysis/Pipelines/PHENOM_DLMUSE_2025/China_PekingUnv/Results/China_PekingUnv_DLMUSE_Volumes.csv,,,,,,,,,,,,,,,,,
PHENOM,China-Tianji-Anning-Hospital,Psychosis data from China Tianji-Anning Hospital,200,0,54,34.7 ± 10.4,China,NA,NA,Hospital-based neuro cohort,NA,0,0,0,0,0,0,,,https://pubmed.ncbi.nlm.nih.gov/27618693/,,,"The PHENOM study is funded by NIA grant R01MH112070 and by the PRONIA project as funded by the European Union 7th Framework Program grant 602152. Other supporting funds are 5U01AG068057, 1U24AG074855, R01MH119219 and S10OD023495.",,,/cbica/projects/PsychAnalysis,NA,,NA,,NA,NA,,,,,,,,,/cbica/projects/PsychAnalysis/Pipelines/PHENOM_DLMUSE_2025/China_TianjiAnningHospital/Results/China_TianjiAnningHospital_DLMUSE_Volumes.csv,,,,,,,,,,,,,,,,,
PHENOM,China-Xijing-Hospital,Psychosis Xijing Hospital,45,0,51.1,26.1 ± 5.3,China,NA,NA,Hospital-based neuro cohort,NA,0,0,0,0,0,0,,,,,,,,,/cbica/projects/PsychAnalysis,NA,,NA,,NA,NA,,,,,,,,,/cbica/projects/PsychAnalysis/Pipelines/PHENOM_DLMUSE_2025/China_XijingHospital/Results/China_XijingHospital_DLMUSE_Volumes.csv,,,,,,,,,,,,,,,,,
PHENOM,ESNA,NA,92,0,33.7,27.1 ± 6.1,NA,NA,NA,NA,0,0,0,0,0,0,,,,,,,,,,/cbica/projects/PsychAnalysis,NA,,NA,,NA,NA,,,,,,,,,/cbica/projects/PsychAnalysis/Pipelines/PHENOM_DLMUSE_2025/ESNA/Results/ESNA_DLMUSE_Volumes.csv,,,,,,,,,,,,,,,,,
PHENOM,Enigma,Enhancing Neuro Imaging Genetics through Meta-Analysis,362,0,48.1,37.8 ± 13.1,International,2009,TRUE,Imaging genetics consortium,neuroimaging,0,0,0,0,1,1,,,,,,,,,/cbica/projects/PsychAnalysis,NA,,NA,,NA,NA,,,,,,,,,/cbica/projects/PsychAnalysis/Pipelines/PHENOM_DLMUSE_2025/Enigma/Results/Enigma_DLMUSE_Volumes.csv,,,,,,,,,,,,,,,,,
PHENOM,GAP,Genomics of Alzheimer’s Project,199,0,43.7,27.2 ± 7.4,NA,NA,NA,NA,0,0,0,0,0,0,,,,,,,,,,/cbica/projects/PsychAnalysis,NA,,NA,,NA,NA,,,,,,,,,/cbica/projects/PsychAnalysis/Pipelines/PHENOM_DLMUSE_2025/GAP/Results/GAP_DLMUSE_Volumes.csv,,,,,,,,,,,,,,,,,
PHENOM,Melbourne,Melbourne Ageing Study,288,0,31.6,25.8 ± 9.3,Australia,NA,NA,University of Melbourne cohorts,NA,0,0,0,0,1,0,,,,,,,,,/cbica/projects/PsychAnalysis,NA,,NA,,NA,NA,,,,,,,,,/cbica/projects/PsychAnalysis/Pipelines/PHENOM_DLMUSE_2025/Melbourne/Results/Melbourne_DLMUSE_Volumes.csv,,,,,,,,,,,,,,,,,
PHENOM,NUSDAST,Northwestern University Schizophrenia Data and Software Tool,,,,,,,,,,,,,,,,,,https://www.frontiersin.org/journals/neuroinformatics/articles/10.3389/fninf.2013.00025/full,,,,,,/cbica/projects/PsychAnalysis,NA,,NA,,NA,NA,,,,,,,,,/cbica/projects/PsychAnalysis/Pipelines/PHENOM_DLMUSE_2025/NUSDAST/Results/NUSDAST_DLMUSE_Volumes.csv,,,,,,,,,,,,,,,,,
PHENOM,PAFIP,Program of first episode psychosis (PAFIP) study,316,0,39.2,30.0 ± 8.4,Spain,2000,TRUE,First-episode psychosis cohort,psychosis,0,0,0,1,0,0,,,,,,,,,/cbica/projects/PsychAnalysis,NA,,NA,,NA,NA,,,,,,,,,/cbica/projects/PsychAnalysis/Pipelines/PHENOM_DLMUSE_2025/PAFIP/Results/PAFIP_DLMUSE_Volumes.csv,,,,,,,,,,,,,,,,,
PHENOM,UMC-Utrecht,University Medical Center Utrecht Brain Imaging Study,617,0,34.4,31.3 ± 11.3,Netherlands,NA,NA,Medical center cohorts,NA,0,0,0,0,1,0,,,,,,,,,/cbica/projects/PsychAnalysis,NA,,NA,,NA,NA,,,,,,,,,/cbica/projects/PsychAnalysis/Pipelines/PHENOM_DLMUSE_2025/UMC_Utrecht_ffe/Results/UMC_Utrecht_ffe_DLMUSE_Volumes.csv;/cbica/projects/PsychAnalysis/Pipelines/PHENOM_DLMUSE_2025/UMC_Utrecht_T13Dsch/Results/UMC_Utrecht_T13Dsch_DLMUSE_Volumes.csv,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
